443 related articles for article (PubMed ID: 29902522)
1. Role of cAMP and phosphodiesterase signaling in liver health and disease.
Wahlang B; McClain C; Barve S; Gobejishvili L
Cell Signal; 2018 Sep; 49():105-115. PubMed ID: 29902522
[TBL] [Abstract][Full Text] [Related]
2. cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease.
Elnagdy M; Barve S; McClain C; Gobejishvili L
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33050657
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.
Rodriguez WE; Wahlang B; Wang Y; Zhang J; Vadhanam MV; Joshi-Barve S; Bauer P; Cannon R; Ahmadi AR; Sun Z; Cameron A; Barve S; Maldonado C; McClain C; Gobejishvili L
Hepatology; 2019 Dec; 70(6):1958-1971. PubMed ID: 31081957
[TBL] [Abstract][Full Text] [Related]
4. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
5. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases.
Schmidt M; Cattani-Cavalieri I; Nuñez FJ; Ostrom RS
Curr Opin Pharmacol; 2020 Apr; 51():34-42. PubMed ID: 32622335
[TBL] [Abstract][Full Text] [Related]
7. Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease.
Vonghia L; Van Herck MA; Weyler J; Francque S
Front Immunol; 2019; 10():563. PubMed ID: 30972062
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway.
Li Z; Feng PP; Zhao ZB; Zhu W; Gong JP; Du HM
Biochem Biophys Res Commun; 2019 Feb; 510(1):20-26. PubMed ID: 30683312
[TBL] [Abstract][Full Text] [Related]
9. Regulating cellular cyclic adenosine monophosphate: "Sources," "sinks," and now, "tunable valves".
Getz M; Rangamani P; Ghosh P
Wiley Interdiscip Rev Syst Biol Med; 2020 Sep; 12(5):e1490. PubMed ID: 32323924
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase Diversity and Signal Processing Within cAMP Signaling Networks.
Neves-Zaph SR
Adv Neurobiol; 2017; 17():3-14. PubMed ID: 28956327
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cAMP-phosphodiesterase activity in bovine seminal plasma.
Bergeron A; Aragon JP; Guillemette C; Hébert A; Sullivan R; Blondin P; Richard FJ
Andrology; 2016 Nov; 4(6):1123-1130. PubMed ID: 27565610
[TBL] [Abstract][Full Text] [Related]
13. Hepatic non-parenchymal cells: Master regulators of alcoholic liver disease?
Seo W; Jeong WI
World J Gastroenterol; 2016 Jan; 22(4):1348-56. PubMed ID: 26819504
[TBL] [Abstract][Full Text] [Related]
14. Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development.
Thapa K; Grewal AS; Kanojia N; Rani L; Sharma N; Singh S
Curr Drug Discov Technol; 2021; 18(3):333-353. PubMed ID: 31965945
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors.
Mehta A; Patel BM
Life Sci; 2019 Aug; 230():150-161. PubMed ID: 31125564
[TBL] [Abstract][Full Text] [Related]
16. PDE2 at the crossway between cAMP and cGMP signalling in the heart.
Weber S; Zeller M; Guan K; Wunder F; Wagner M; El-Armouche A
Cell Signal; 2017 Oct; 38():76-84. PubMed ID: 28668721
[TBL] [Abstract][Full Text] [Related]
17. PDE/cAMP/Epac/C/EBP-β Signaling Cascade Regulates Mitochondria Biogenesis of Tubular Epithelial Cells in Renal Fibrosis.
Ding H; Bai F; Cao H; Xu J; Fang L; Wu J; Yuan Q; Zhou Y; Sun Q; He W; Dai C; Zen K; Jiang L; Yang J
Antioxid Redox Signal; 2018 Sep; 29(7):637-652. PubMed ID: 29216750
[TBL] [Abstract][Full Text] [Related]
18. Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence.
Wen RT; Liang JH; Zhang HT
Adv Neurobiol; 2017; 17():413-444. PubMed ID: 28956341
[TBL] [Abstract][Full Text] [Related]
19. Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?
Boye A; Zou YH; Yang Y
World J Gastroenterol; 2016 Jan; 22(1):50-71. PubMed ID: 26755860
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide phosphodiesterase inhibition as a potential therapeutic target in renal ischemia reperfusion injury.
Thapa K; Singh TG; Kaur A
Life Sci; 2021 Oct; 282():119843. PubMed ID: 34298037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
